420 related articles for article (PubMed ID: 12064681)
1. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
2. PET scan in lung cancer: current recommendations and innovation.
Vansteenkiste JF; Stroobants SS
J Thorac Oncol; 2006 Jan; 1(1):71-3. PubMed ID: 17409830
[TBL] [Abstract][Full Text] [Related]
3. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
Vansteenkiste JF; Stroobants SG
Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
[TBL] [Abstract][Full Text] [Related]
4. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
5. Value of FDG-PET in the management of non-small cell lung cancer.
Stroobants S; Verschakelen J; Vansteenkiste J
Eur J Radiol; 2003 Jan; 45(1):49-59. PubMed ID: 12499064
[TBL] [Abstract][Full Text] [Related]
6. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography in the management of non-small cell lung cancer.
Vansteenkiste JF; Stroobants SG
Hematol Oncol Clin North Am; 2004 Feb; 18(1):269-88. PubMed ID: 15005293
[TBL] [Abstract][Full Text] [Related]
9. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
[TBL] [Abstract][Full Text] [Related]
10. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
11. Significance of a new fluorodeoxyglucose-positive lesion on restaging positron emission tomography/computed tomography after induction therapy for non-small-cell lung cancer.
Collaud S; Lardinois D; Tischler V; Steinert HC; Stahel R; Weder W
Eur J Cardiothorac Surg; 2012 Mar; 41(3):612-6. PubMed ID: 22219415
[TBL] [Abstract][Full Text] [Related]
12. Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer.
Usmanij EA; de Geus-Oei LF; Bussink J; Oyen WJ
Curr Opin Pulm Med; 2015 Jul; 21(4):314-21. PubMed ID: 25978629
[TBL] [Abstract][Full Text] [Related]
13. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
[TBL] [Abstract][Full Text] [Related]
14. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
16. Value of FDG PET in the management of NSCLC.
Ukena D; Hellwig D
Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
[TBL] [Abstract][Full Text] [Related]
17. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG
J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions.
Gupta NC; Graeber GM; Bishop HA
Chest; 2000 Mar; 117(3):773-8. PubMed ID: 10713005
[TBL] [Abstract][Full Text] [Related]
19. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.
Stokkel MP; Bakker PF; Heine R; Schlösser NJ; Lammers JW; Van Rijk PP
Nucl Med Commun; 1999 Nov; 20(11):1001-7. PubMed ID: 10572909
[TBL] [Abstract][Full Text] [Related]
20. Targeted lymph node biopsy in mediastinoscopy using 3D FDG-PET/CT movies: a feasibility study.
Siepel FJ; de Bruin WI; van Duyn EB; Steenvoorde P; Wagenaar NR; Slump CH; van Dalen JA
Nucl Med Commun; 2012 Apr; 33(4):439-44. PubMed ID: 22311052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
